Clinical Trial Update: Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the food effect of alisertib (MLN8237) in participants with advanced solid tumors or lymphomas; study completed with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Solid Tumors, Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2019-06-21